PFEIFER, Andrea,MUHS, Andreas,WATTS, Ryan,PIHLGREN, Maria
申请号：
ES08838455
公开号：
ES2609918T3
申请日:
2008.10.03
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
A pharmaceutical composition for use in the treatment of a subject who is suffering from an eye disease associated with pathological abnormalities / changes related to beta-amyloid in the tissues of the visual system, selected from (i) glaucoma, (ii) optic neuritis, (iii) ocular amyloidosis characterized by anomalous conjunctival vessels, dry keratoconjunctivitis, papillary abnormalities, vitreous opacities and / or secondary glaucoma, and (iv) reticular dystrophy, which comprises a therapeutically effective amount of a humanized antibody or a functional part thereof, which recognizes and binds to at least one distinct site in the beta-amyloid protein, wherein the humanized antibody or a functional part thereof comprises: (a) a heavy chain CDR1 having the amino acid sequence of SEQ ID NO : one； a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 2； a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 3； a light chain CDR1 having the amino acid sequence of SEQ ID NO: 4； a light chain CDR2 having the amino acid sequence of SEQ ID NO: 5, the RVSNRFS amino acid sequence, or the KVSSRFS amino acid sequence； and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 6, and (b) an Fc region of IgG1 with reduced binding to Fc.gamma.R that has an amino acid modification in any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324 , 327, 329, 333 335, 338, 340, 373, 378, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the Fc region of IgG1.Una composición farmacéutica para uso en el tratamiento de un sujeto que está aquejado de una enfermedad ocular asociada con anomalías patológicas/cambios relacionados con la beta-amiloide en los tejidos del sistema visual, seleccionados de (i) glaucoma, (ii) neuritis óptica, (iii) amiloidosis ocular caracterizada por vasos conjuntivales anómalos, queratoconjuntivitis seca, anomalías papilares, opacidade
